Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605534055 | ||
| 003 | CHVBK | ||
| 005 | 20210128100841.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10928-015-9447-8 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10928-015-9447-8 | ||
| 100 | 1 | |a Shah |D Dhaval |u Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York at Buffalo, 455 Kapoor Hall, 14214-8033, Buffalo, NY, USA |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics |h [Elektronische Daten] |c [Dhaval Shah] |
| 520 | 3 | |a Increasingly sophisticated protein engineering efforts have been undertaken lately to generate protein therapeutics with desired properties. This has resulted in the discovery of the next generation of protein therapeutics, which include: engineered antibodies, immunoconjugates, bi/multi-specific proteins, antibody mimetic novel scaffolds, and engineered ligands/receptors. These novel protein therapeutics possess unique physicochemical properties and act via a unique mechanism-of-action, which collectively makes their pharmacokinetics (PK) and pharmacodynamics (PD) different than other established biological molecules. Consequently, in order to support the discovery and development of these next generation molecules, it becomes important to understand the determinants controlling their PK/PD. This review discusses the determinants that a PK/PD scientist should consider during the design and development of next generation protein therapeutics. In addition, the role of systems PK/PD models in enabling rational development of the next generation protein therapeutics is emphasized. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Pharmacokinetic |2 nationallicence | |
| 690 | 7 | |a Pharmacodynamic |2 nationallicence | |
| 690 | 7 | |a Protein therapeutics |2 nationallicence | |
| 690 | 7 | |a Biologics |2 nationallicence | |
| 690 | 7 | |a Novel scaffold |2 nationallicence | |
| 690 | 7 | |a ADME |2 nationallicence | |
| 690 | 7 | |a Toxicity |2 nationallicence | |
| 690 | 7 | |a Immunogenicity |2 nationallicence | |
| 773 | 0 | |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/5(2015-10-01), 553-571 |x 1567-567X |q 42:5<553 |1 2015 |2 42 |o 10928 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10928-015-9447-8 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10928-015-9447-8 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 100 |E 1- |a Shah |D Dhaval |u Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York at Buffalo, 455 Kapoor Hall, 14214-8033, Buffalo, NY, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/5(2015-10-01), 553-571 |x 1567-567X |q 42:5<553 |1 2015 |2 42 |o 10928 | ||